Therapy areas covered
12
From oncology and rare disease to vaccines, transplant, and women’s health.
Pharmaceutical Therapy Areas Market Research Across MENA, UK, and Europe
BioNixus has led pharmaceutical market research engagements across 12 therapy areas and more than 88 indications, partnering with global and regional pharma teams to translate stakeholder evidence into launch, market access, and commercial decisions. Start from our healthcare market research hub to explore country coverage and service depth.
Last updated: 2026-04-22. For regional strategy context, review the Middle East pharmaceutical market research pillar and GCC healthcare market research agency.
Indications mapped
88+
Specific disease areas with stakeholder-ready research architecture.
Engagements delivered
300+
Across MENA, UK, and Europe with global and regional pharma clients.
Pharmaceutical Therapy Areas We Cover
Oncology and Hemato-Oncology
Solid tumor and hematology market research covering treatment pathway behavior, biomarker-led decisions, and evidence expectations across MENA, UK, and Europe.
View 13 indications covered
- Breast cancer
- Colorectal cancer
- Gastric cancer
- Head and neck cancer
- Hepatocellular carcinoma
- Lung cancer (NSCLC and SCLC)
- Ovarian cancer
- Prostate cancer
- Leukemia (AML, ALL, CML, CLL)
- Multiple myeloma
- Non-Hodgkin lymphoma (DLBCL, PTCL, NHL)
- Renal cell carcinoma
- Soft tissue sarcoma
Rare and Genetic Diseases
Small-population research for rare and genetic disease portfolios with incidence-aware sampling, specialist access, and patient-pathway mapping.
View 14 indications covered
- Hemophilia A and B
- Beta thalassemia (intermedia, major, minor)
- Sickle cell disease
- Aplastic anemia
- Systemic lupus erythematosus
- Lysosomal acid lipase deficiency (LAL-D)
- Idiopathic thrombocytopenic purpura (ITP)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Myasthenia gravis (MG)
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)
- Hypophosphatasia (HPP)
- ADA-SCID and metachromatic leukodystrophy (MLD)
- Hidradenitis suppurativa
Immunology and Inflammation
Immunology and autoimmune research mapping switching drivers, evidence thresholds, and long-term positioning for biologic and advanced therapies.
View 7 indications covered
- Rheumatoid arthritis
- Psoriasis
- Psoriatic arthritis
- Ulcerative colitis
- Crohn’s disease
- Atopic dermatitis
- Ankylosing spondylitis
Neurology and Neuropsychiatry
Neurology and mental health research covering long-term adherence, access realities, and prescriber confidence across specialist and primary-care settings.
View 9 indications covered
- Multiple sclerosis
- Epilepsy
- Migraine
- Parkinson’s disease
- Alzheimer’s disease
- Major depressive disorder
- Schizophrenia
- Bipolar disorder
- Diabetic peripheral neuropathic pain (DPNP)
Cardiovascular and Metabolic
Cardiometabolic intelligence covering switching drivers, adherence, guideline interpretation, and payer-adjacent access realities.
View 9 indications covered
- Type 2 diabetes
- Dyslipidemia
- Hypertension
- Coronary artery disease (CAD)
- Acute coronary syndrome (ACS)
- Peripheral arterial disease (PAD)
- Acute and chronic heart failure
- Angina
- Obesity and weight management
Respiratory
Respiratory market research for portfolio strategy, adherence, and guideline-aligned adoption in chronic and acute pathways.
View 5 indications covered
- Asthma (mild, moderate, severe)
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis
- Idiopathic pulmonary fibrosis (IPF)
- Cystic fibrosis
Infectious Diseases and Hepatology
Infectious disease programs spanning antivirals, hepatology, and antimicrobial stewardship research with specialist access in MENA and Europe.
View 6 indications covered
- Hepatitis B
- Hepatitis C
- HIV
- Tuberculosis
- Hospital-acquired infections
- Antimicrobial stewardship programs
Vaccines and Immunization
Vaccine confidence, adoption, and communication research for national programs, private channels, and adult immunization strategies.
View 6 indications covered
- Rotavirus vaccine
- Pneumococcal vaccine
- Meningococcal vaccine
- HPV vaccine
- Influenza and COVID-19 boosters
- Adult immunization programs
Ophthalmology
Ophthalmology research covering retina specialist behavior, device-drug integration, and chronic therapy adherence patterns.
View 4 indications covered
- Wet age-related macular degeneration (wAMD)
- Diabetic macular edema (DME)
- Dry eye disease
- Glaucoma
Urology and Nephrology
Urology and nephrology intelligence for chronic disease pathways, specialist referral dynamics, and institutional procurement.
View 5 indications covered
- Benign prostatic hyperplasia (BPH)
- Erectile dysfunction (ED)
- Overactive bladder
- Chronic kidney disease
- Dialysis and nephrology care
Transplant Medicine
Solid organ transplant research covering induction and maintenance therapy choice, rejection management, and center-level protocols.
View 4 indications covered
- Renal transplantation
- Hepatic transplantation
- Cardiac transplantation
- Immunosuppressive regimen research
Women’s Health and General Medicine
Primary care, women’s health, and consumer-health research covering prescriber behavior, OTC switching, and patient-reported outcomes.
View 6 indications covered
- Contraception and hormonal therapies
- Menopause management
- Infant nutrition and formulas
- Pain management
- Peptic ulcer disease
- Wound care
How Therapy Area Research Supports Pharma Decisions
Launch readiness
Segment demand, prioritize accounts, and align messaging before major launch investment in each therapy area.
Market access intelligence
Map payer, committee, and procurement behavior so formulary and tender decisions are anticipated, not reacted to.
Stakeholder segmentation
Specialist, institutional, and primary-care archetypes built from real prescribing behavior rather than self-reported claims.
Lifecycle optimization
Post-launch pulse studies, adherence research, and communication testing to protect share and accelerate growth.
Related Research Capabilities and Country Pages
Frequently Asked Questions
Which pharmaceutical therapy areas does BioNixus cover in market research?
BioNixus covers oncology, rare and genetic diseases, immunology, neurology and neuropsychiatry, cardiometabolic, respiratory, infectious diseases and hepatology, vaccines, ophthalmology, urology and nephrology, transplant medicine, and women’s health and general medicine across MENA, UK, and Europe.
How does BioNixus design therapy-specific pharma market research?
Programs start from the business decision and work backward to stakeholder architecture, incidence-aware sampling, and quality governance. Quantitative and qualitative methods are combined so commercial, medical, and market access teams work from one evidence framework.
Can BioNixus support rare disease and small-population therapy research?
Yes. Rare disease programs use referral-led specialist recruitment, caregiver and patient access routes where permitted, and incidence-aware study design so small populations produce decision-grade evidence.
Do therapy area studies cover market access and payer dynamics?
Yes. Most therapy studies include an access layer covering payer, committee, and procurement behavior alongside clinical decision drivers, so launch, formulary, and lifecycle decisions share the same evidence base.
Which countries can BioNixus execute therapy-specific pharma research in?
Core execution spans Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, the wider MENA region, the United Kingdom, and Europe, with harmonized cores and localized modules for cross-country comparability.
Plan Your Next Therapy-Area Research Program
Tell us the therapy area, decision to be made, and target countries. We will return a proposal-ready study design with stakeholder architecture, quality governance, and an activation plan.